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Abstract
Glioblastoma multiforme (GBM) is a lethal cancer that exerts potent immune suppression. Hypoxia is a predominant feature
of GBM, but it is unclear to the degree in which tumor hypoxia contributes to this tumor-mediated immunosuppression.
Utilizing GBM associated cancer stem cells (gCSCs) as a treatment resistant population that has been shown to inhibit both
innate and adaptive immune responses, we compared immunosuppressive properties under both normoxic and hypoxic
conditions. Functional immunosuppression was characterized based on production of immunosuppressive cytokines and
chemokines, the inhibition of T cell proliferation and effector responses, induction of FoxP3+ regulatory T cells, effect on
macrophage phagocytosis, and skewing to the immunosuppressive M2 phenotype. We found that hypoxia potentiated the
gCSC-mediated inhibition of T cell proliferation and activation and especially the induction of FoxP3+T cells, and further
inhibited macrophage phagocytosis compared to normoxia condition. These immunosuppressive hypoxic effects were
mediated by signal transducer and activator of transcription 3 (STAT3) and its transcriptionally regulated products such as
hypoxia inducible factor (HIF)-1a and vascular endothelial growth factor (VEGF). Inhibitors of STAT3 and HIF-1a down
modulated the gCSCs’ hypoxia-induced immunosuppressive effects. Thus, hypoxia further enhances GBM-mediated
immunosuppression, which can be reversed with therapeutic inhibition of STAT3 and HIF-1a and also helps to reconcile the
disparate findings that immune therapeutic approaches can be used successfully in model systems but have yet to achieve
generalized successful responses in the vast majority of GBM patients by demonstrating the importance of the tumor
hypoxic environment.
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Introduction
We and other investigators have recently demonstrated that the
GBM-associated cancer stem cells (gCSCs) participate in tumor-
mediated immunosuppression by both secreted and membrane-
associated mechanisms and inhibit both innate and adaptive
immunity [1,2,3,4]. Specifically, gCSCs markedly inhibited
adaptive T cell proliferation and activation and induced regulatory
T cells by both direct cell-to-cell contact and secreted soluble
factors in both donor and autologous T cell assays with similar
results [2,3]. Furthermore, the gCSCs also induce macrophage/
microglia to assume an immunosuppressive M2 phenotype
mediated by the phosphorylated signal transducer and activator
of transcription (pSTAT3) pathway with impaired innate functions
that could be blocked by WP1066 [4]. These findings conflict with
those that suggest that the gCSC may be targeted using a variety of
immunotherapeutic approaches [5,6,7]. The reconciliation of this
disparity may reside in environmental factors that are minimized
or negated in cell lines that are perpetuated in vitro. Because gCSCs
are a heterogeneous cell population, and immunosuppressive
properties provide no survival benefit in a cell-culture environ-
ment, selective pressures may favor the loss of immunosuppressive
phenotypes over time. This important consideration may falsely
lead an investigator to implement an immune therapeutic strategy
based on preclinical data that has artificially minimized the
influence of tumor mediated immunosuppression.
Hypoxic microenvironments are a frequent characteristic of
GBM that are the consequences of morphologically and
functionally inappropriate neovascularization, irregular blood
flow, anemia, and the high oxygen consumption of rapidly
proliferating malignant cells [8]. These hypoxic microenviron-
ments are a powerful stimulus for the expression of genes involved
in tumor cell proliferation and angiogenesis [9]. Tumor hypoxia
can activate the pSTAT3 immunosuppressive pathway thereby
triggering the downstream synthesis of hypoxia inducible factor
(HIF)-1a that can then induce regulatory T cells [10] and vascular
endothelial growth factor (VEGF)[11,12], which in addition to
promoting angiogenesis is also immunosuppressive [13,14]. In
addition, other glioma-elaborated immune suppressive cytokines
such as transforming growth factor (TGF)-b [15,16,17], soluble
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(CCL)-2 [20,21] and galectin-3 [22,23] have also been shown to
be associated with or induced by HIF-1a and hypoxia
[24,25,26,27,28].
The STAT3 pathway, which is induced in the various immune
populations, has been shown to be a potent regulator of anti-
inflammatory responses in both innate [29] and adaptive
immunity [30], including immunosuppression potentiated by the
gCSC [2,4]. CNS macrophages (microglia), which are the
dominant infiltrating immune cells in GBM and the principle
mediators of innate immunity within the tumor [31,32], become
tumor-associated macrophages (TAMs) when exposed to the
hypoxic tumor microenvironment (TAMs) [33,34]. TAMs become
polarized toward immunosuppressive and tumor supportive
phenotypes (M2) via the STAT3 pathway and then contribute
to angiogenesis and tumor invasion [26]. We have demonstrated
that these TAMs, which arise from circulating monocytes that are
recruited into the tumor microenvironment [35], can be
modulated by the gCSCs by inducing an immunosuppressive
phenotype via the STAT3 pathway[4]. Since HIF-1a can promote
the expansion of CD133-positive gCSCs [36,37], it is possible that
hypoxia induces a feed-forward mechanism of tumor-mediated
immunosuppression.
We suspected that hypoxia potentiates the ability of the gCSC
to evade immune surveillance that could account for, in part, the
discrepancy between investigators that demonstrate immunolog-
ical clearance of this population [5,6,7] and the grim reality of
recurrence and failure of gCSC eradication even in the setting
immune therapeutic approaches. We therefore hypothesized that hypoxia
would further potentiate the innate and adaptive immunosuppressive properties
of gliomas which could be reversed by inhibiting hypoxia induced pathways
such as pSTAT3. To determine whether we could reverse the
gCSC-mediated immunosuppressive effects of hypoxia, we tested
the pSTAT3 and HIF-1a inhibitor WP1066 [38] and WP744, an
anthracycline compound [39] with suspected HIF-1a inhibitory
effects [40].
Materials and Methods
Ethical Treatment of Research Subjects and Patient
Consent
Each patient provided written informed consent for tumor
tissues, and this study was conducted under protocol #LAB03-
0687, which was approved by the institutional review board of
The University of Texas M. D. Anderson Cancer Center.
Derivation of human gCSCs
GBM specimens were processed within 4 hours after resection.
The four separate gCSCs used in this study were isolated from four
different individual GBM patients. They were washed with
DMEM-F-12 medium, disassociated as previously described
[41], and have been previously characterized [2,3,4]. The gCSCs
were grown in neurosphere medium (DMEM-F-12 medium
containing 20 ng/ml of epidermal growth factor, basic fibroblast
growth factor (Sigma, St. Louis, MO), and B27 (1:50; Invitrogen,
Carlsbad, CA). To minimize possible phenotypic changes in
gCSCs due to prolonged maintenance in vitro and multiple
passages, early passage gCSCs were frozen in neurosphere
medium containing 5% DMSO and stored at 270uC. After
thawing, gCSCs were used in experiments after 1 or 2 passages.
Hypoxia induction
Dissociated gCSCs (1.5610
6 cells) were plated in T-25 flasks in
4 ml of neurosphere medium and cultured under normoxic
conditions for 48 h to allow the cells to re-enter log-growth phase.
The cells were then moved to a hypoxia chamber (Sanyo
Manufacturing) at 1% O2 for another 24 h. Alternatively, cells
were treated with 100 mM of hypoxia-mimic chemical desferriox-
amine mesylate (DFX; Sigma).
Antibodies and reagents
Tissue-culture grade monoclonal antibodies to CD3 (OKT3)
and CD28 (28.6) were obtained from eBioscience. The cell surface
was stained with phycoerythrin (PE), fluorescein isothiocyanate
(FITC), or allo-phycocyanin-conjugated (APC) antibodies against
the following proteins: CD3, CD4, CD8, major histocompatibility
complex (MHC) I, MHC II, CD40, CD80, CD86, and B7-H1
(BD Pharmingen, San Diego, CA) and CD133 (Miltenyi Biotech,
Auburn, CA). To detect intracellular cytokines, PE-conjugated
antibodies against interleukin (IL)-2 and interferon (IFN)-c (R&D
Systems) were used. To detect pSTAT3, PE-conjugated antibodies
against pSTAT3 (BD Pharmingen, San Diego, CA) were used.
Appropriate isotype controls were used for each antibody.
The inhibitor agents WP1066 and WP744 were synthesized and
supplied by Waldemar Priebe. WP1066 was stored as a 10 mM
stock solutions in dimethyl sulfoxide and diluted with PBS and
WP744 was stored as a 10 mM stock solutions in N,N-dimethyla-
cetamide. WP1066 is a specific and potent inhibitor of STAT3 [38]
and of down-stream STAT3-regulated products (such as HIF-1a)
that achieves in vivo physiological doses of 2 mM, including within
the central nervous system [42]. WP744 is an anthracycline
compound [39] that is suspected to inhibit HIF-1a [40] and
achieves in vivo physiological doses of 0.1 mM (unpublished data).
Only WP1066 possesses significant pSTAT3 inhibitory activity.
The cell viability of the gCSCs based on MTT (dimethyl thiazolyl
diphenyltetrazolium)assaysisnotaffected bydosesof2 and0.1 mM
of WP1066 or WP744, respectively.
ELISA
Supernatant medium from the gCSC cell cultures were assayed
for cytokine concentrations using ELISA kits as described by the
manufacturer (R&D Systems). These supernatants were collected
from 3610
6 cells after 5 d in culture and stored at 220uC. The
supernatants were added in duplicate to appropriate pre-coated
plates. After the plates were washed, horseradish peroxidase-
conjugated detection antibody was added. The substrate used for
color development was tetramethylbenzidine. The optical density
was measured at 450 nm with a microplate reader (Spectra Max
190; Molecular Devices, Sunnyvale, CA), and chemokine concen-
trations were quantified using SoftMax Pro software (Molecular
Devices). The detection limits for CC chemokine ligand 2 (CCL-2)
were 5 pg/ml; TGF-b1, 16 pg/ml; IL-10, 5 pg/ml; soluble colony-
stimulating factor (sCSF)-1, 8 pg/mL; VEGF, 5 pg/ml; Galectin-3,
10 pg/ml; and macrophage inhibitory cytokine (MIC)-1, 8 pg/ml.
Human peripheral blood mononuclear cells (PBMCs)
PBMCs were prepared from healthy donor blood (Gulf Coast
Blood Center, Houston, TX). CD14+ monocytes were purified
from PBMCs by positive selection using CD14 microbeads
(Miltenyi Biotech, Auburn, CA), and CD3+ T cells were purified
from PBMCs by negative selection using a Pan T Cell Isolation
Kit II (Miltenyi Biotech, Auburn, CA), according to the
manufacturer’s instructions.
Human monocyte assays
5610
5 CD14+ monocytes were incubated with 500 mL( 1 610
6
cells/mL) of supernatant medium from gCSCs cultured in both
Hypoxia Potentiates Glioma Immunosuppression
PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e16195normoxic and hypoxic conditions, as well as in neurosphere
medium as controls. Induction of pSTAT3 was determined by
flow cytometry after overnight incubation. Expression of the cell
surface markers MHC I, MHC II, CD80, CD86, CD163, and
CD204 was determined by flow cytometry after 48 h of
incubation. After 72 h of incubation, monocytes were harvested
for phagocytosis assays, and supernatants were collected for
cytokine ELISA.
Flow cytometry
FITC-conjugated anti-CD4 (RPA-T4) and APC-conjugated
anti-CD8 (RPA-T8) antibodies were used for cell surface staining.
Sub-analysis of the T cell populations was based on the gated
surface expression of CD4 and CD8. To detect FoxP3 protein
expression, the surface stained cells were further subjected to
intracellular staining with PE-conjugated monoclonal antibodies to
human FoxP3 (clone PCH101, eBiosciences) using staining buffers
and conditions specified by the manufacturer. For intracellular
cytokine staining, cells were stimulated for 6 h in the presence of
50 ng/ml phorbol myristate acetate (PMA), 500 ng/ml ionomycin
(Sigma-Aldrich), and 2 mM monensin (GolgiStop, BD Sciences).
Then the cells were incubated with FITC-conjugated anti-CD4
and APC-conjugated anti-CD8 (RPA-T8) antibodies for surface
staining followed by intracellular staining using PE-conjugated
anti-mouse IFN-c (4S.B3) antibody and FIX/PERM buffers (BD
Pharmingen) according to the manufacturer’s instructions. For
HIF1a intracellular staining, gCSCs were first fixed with cold 4%
paraformaldehyde at room temperature for 10 minutes; following
fixation, the cells were washed and permeabilized by 1% saponin
on ice for 30 minutes, and then stained by APC-conjugated anti-
human HIF-1a antibody (R&D Systems) for 45 minutes at room
temperature in the dark. Intracellular p-STAT3 intracellular
staining was performed as previously described [43]. Flow
cytometry acquisition was done with a FACSCaliber (Becton
Dickinson, San Diego, CA), and data analysis was with FlowJo
software (TreeStar, Ashland, OR).
Cell proliferation assay and regulatory T cell induction
assay
The conditioned medium from the gCSCs was added to 2 mM
CFSE-labeled 3610
5 PBMCs/ml in the presence of 1 mg/ml pre-
bound anti-CD3/anti-CD28 antibodies. After 72 h, T cell
proliferation was measured by division of CFSE-labeled cells as
recorded with flow cytometry. The inhibition of T cell
proliferation was represented by the percentage decrease of
CSFE+ divided T cells compared to neurosphere medium control.
To detect FoxP3+ regulatory T cells, CD4 surface staining and
then FoxP3 intracellular staining were performed on immune cells
cultured for 96 h.
Phagocytosis assay
CD14+ monocytes were incubated with either normoxic or
hypoxic gCSC-conditioned medium for 72 h. Positive control
monocytes were incubated with neurosphere medium for 72 h.
Cell viability was assessed by Trypan Blue exclusion, and live
monocytes were transferred to a 96-well plate at a concentration of
1.0610
5 cells/well and incubated at 37uC in a humidified
atmosphere containing 95% air/5% CO2 for 1 h to allow the
cells to adhere. The cells were then incubated with pHrodo E. coli
BioParticles (Invitrogen) suspended in PBS for 2 h at 37uCa t
atmospheric CO2 levels. Cells were examined using fluorescence
microscopy, and phagocytosis was quantified by measuring the
mean fluorescence intensity per cell and corrected for background
using Adobe Photoshop CS software. Percent phagocytosis levels
relative to the control were calculated for each experimental
condition.
Western Blot
After exposure to normoxia and hypoxic conditions, gCSCs were
harvested, pelleted by centrifugation, and rinsed with ice-cold PBS
at 1,500-rpm for 5 min. The cells were lysed for 30 min in ice-cold
lysis buffer (50-mM Tris–HCl [pH 8.0], 150-mM NaCl, 1-mM
EDTA)containing1%Triton-X-100andphosphataseandprotease
inhibitors (Sigma-Aldrich). The lysates were centrifuged at 14,000-
rpm for 10 min at 4uC. The supernatants were collected and
quantified for protein content. Equal amounts of proteins (40-mg)
were electrophoretically fractionated in 8% sodium dodecyl sulfate
(SDS)-polyacrylamidegels,transferredtonitrocellulosemembranes,
and subjected to immunoblot analysis with specific antibodies
against pSTAT3 (Tyr705), total STAT3 (both are from Cell
Signaling Technology, Inc., Danvers, MA), HIF-1a (Novus
Biologicals, Littleton, CO) and b-actin (Sigma-Aldrich). Autoradi-
ography of the membranes was performed using Amersham ECL
Western-blotting detection reagents (Amersham Biosciences).
Statistical analysis
All values were calculated as means and 95% confidence
intervals (CIs) from at least three independent experiments.
Student’s t test was used to test for differences in the means
between two groups. P values of less than 0.05 were considered to
be statistically significant. All statistical analyses were performed
using the Statistical Package for the Social Sciences v.12.0.0
(SPSS, Chicago, IL). Error bars represent the s.d.
Results
Hypoxia enhances the production of immunosuppressive
cytokines by the gCSCs
To determine if hypoxia further potentiated gCSC elaborated
immunosuppressive cytokines, the gCSCs (n=4) were assayed for
immunosuppressive cytokines by ELISA. Hypoxia enhanced
immunosuppressive VEGF secretion in 3 out of 4 gCSCs (750–
1160 pg/10
6 cells/24 hours under normoxic conditions versus
1290–3300 pg/10
6 cells/24 hours under hypoxic conditions, an
increase of 1.1–4.4X) and the monocyte chemokine attractant
sCSF-1 in 2 out of 4 gCSCs (4.2–100 pg/10
6 cells/24 hours under
normoxic conditions versus 5.6–114 pg/10
6 cells/24 hours, an
increase of 1.1–1.7X). Trends were also observed showing hypoxia
increasing the T cell apoptosis inducing cytokine galectin-3
secretion in 3 out of 4 gCSCs (4.2–1810 pg/10
6 cells/24 hours
under normoxic conditions versus 88.9–8110 pg/10
6 cells/
24 hours under hypoxic conditions, an increase of 4.5-101X),
and the regulatory T cell chemokine attractant CCL-2 in 3 out of
4 gCSCs (5.6–761 pg/10
6 cells/24 hours under normoxic condi-
tions versus 56.1–2465 761 pg/10
6 cells/24 hours under hypoxic
conditions, an increase of 1.5–10.1X) (Fig. 1). Hypoxia induced
variable responses in TGF-b1 production and failed to enhance
production of MIC-1 (data not shown).
Hypoxia augments the ability of gCSCs to inhibit T cell
adaptive immunity
To determine if hypoxia potentiates the immunosuppressive
effects of gCSCs on T cell activation and proliferation, the gCSCs
(n=4) were placed under both normoxic and hypoxic conditions.
All supernatants from gCSCs cultured under normoxic conditions
inhibited T cell proliferation by approximately 43% (range: 29–
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hypoxiafurtherinhibited T cellproliferationrepresentedbydivision
of CFSE labeled T cells by approximately 64% (range: 52–78%,
P=0.04 comparing hypoxia to normoxia, Fig. 2A). Because
hypoxia is likely to enhance the induction of regulatory T cells,
we tested supernatants from gCSCs grown under normoxic
conditions and found that they caused expansion of the number
of CD4+FoxP3+ regulatory T cells in healthy donor PBMCs by
236% (range: 34%–400%). However, when cultured under hypoxic
conditions, the gCSCs further increased the induction of regulatory
T cellsby342%(range:55%–512%,P=0.05comparinghypoxiato
normoxia, Fig. 2B). To assess for functional activity of T cell
suppression, IFNc production in the CD3/CD28 stimulated T cells
weremeasured after culture with supernatants from gCSCs exposed
to normoxic and hypoxic conditions. We found that hypoxic gCSCs
caused a significant decrease of the IFNc+ T cells compared to
normoxia (51–74% vs 24–53%, P=0.02, Fig. 2C).
Hypoxia enhances the ability of gCSCs to inhibit
phagocytosis in monocytes
To determine whether hypoxia-stressed gCSCs would alter the
expression of MHC and co-stimulatory molecules on monocytes,
which give rise to macrophages, we compared monocytes that
were exposed to gCSC-conditioned medium under hypoxia and
normoxic conditions and then analyzed surface markers by flow
cytometry. Hypoxia-stressed gCSCs did not alter the expression of
CD80, CD86, MHC I, MHC II, cytotoxic T-lymphocyte antigen
(CTLA)-4, or B7-H1 on monocytes in comparison with those
cultured in normoxic conditions (data not shown), indicating that
hypoxia did not alter the gCSC-mediated expression of inflam-
matory markers on the monocytes.
To determine whether the ability of gCSCs to inhibit
phagocytosis in monocytes was increased under hypoxic condi-
tions, phagocytosis assays were performed on monocytes exposed
to medium conditioned by gCSCs under normoxic and hypoxic
conditions. Under normoxic conditions, the gCSC supernatants
(n=4) inhibited phagocytosis in monocytes (Fig. 3A) (to 47%–59%
of the level seen in positive control monocytes exposed to
neurosphere medium alone; P=0.0005). The inhibition of
phagocytosis was further enhanced to a statistically significant
degree under hypoxic conditions (to 26%–39% of positive control)
compared with supernatants from gCSC cultured under normoxic
conditions (P=0.005, paired t-test) in all four gCSCs tested
(Fig. 3B).
Figure 1. Hypoxia increased immunosuppressive cytokine production in gCSCs. Under hypoxic conditions, there was an increase in
production of: VEGF in 3 of 4 gCSCs, galectin-3 in 3 out of 4 gCSCs, sCSF-1 in 3 of 4 gCSCs, and CCL-2 in 3 of 4 gCSCs, as assessed by ELISA. Error bars
are derived from three separate experiments representing the deviation of the associated means between experiments throughout the manuscript.
* P,0.05.
doi:10.1371/journal.pone.0016195.g001
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To ascertain if hypoxia increases gCSC expression of pSTAT3
and HIF-1a, the gCSCs were exposed to hypoxia and normoxic
conditions and the expression levels of pSTAT3 and HIF-1a were
determined by flow cytometry analysis. Hypoxia augmented the
expression of both pSTAT3 (Fig. 4A and B) and HIF-1a (Fig. 4C
and 4D) by 19,87% (average 43%) and 28,86% (average 62%),
respectively. Western blot analysis showed a similar increase of
pSTAT3 and HIF-1a expression, and no change for total STAT3
(Fig. 4E), indicating the increase of pSTAT3 were not due to
general STAT3 changes.
WP744 and WP1066 affect pSTAT3 and HIF-1a activity
To determine if we could reverse the hypoxia-induced
immunosuppression, we first assessed the ability of WP744 and
WP1066 to reverse hypoxia-induced expression of HIF-1a.
WP744 was a more potent inhibitor of HIF-1a and reduced
expression by 53% under conditions of hypoxia, compared to 25%
HIF-1a reduction by WP1066 (Figure 5A and 5B), thereby
essentially abolishing the hypoxia-induced amounts of HIF-1a A
similar but less degree inhibition of HIF-1a was observed under
conditions of normoxia, confirming that these agents possessed
HIF-1a inhibitory properties. However, we found WP744
enhanced pSTAT3 expression, but WP1066 inhibited its expres-
sion under both conditions of normoxia and hypoxia (Figure 5C
and 5D). There were up-regulation of pSTAT3 expression by
25%–184% (P=0.02, paired t-test) in all 4 gCSCs under hypoxia
(Fig. 5D), in contrast to the inhibitory effect of WP1066 (Fig. 5D)
(decrease 24%–68% under hypoxia alone, P=0.0005, paired t-
test), indicating that WP1066 possess inhibitory activity of STAT3
and HIF-1a, whereas WP744 only inhibits HIF-1a.
Inhibition of pSTAT3 and HIF-1a reverses hypoxia
induced immunosuppression
To assess the impact of WP1066 and WP744 on cytokine
secretion in hypoxia-exposed gCSC, the gCSCs were treated with
each inhibitor under conditions of hypoxia. WP1066 reduced
galectin-3 (43%–79%, P=0.02) and sCSF-1 (0%–24%, P=0.05)
production in all four hypoxia-exposed gCSCs, VEGF production
in 3/4 gCSCs (23%–67%, P=0.08), and CCL-2 production in 2/
4 gCSCs (16%–46%, P=0.04). The gCSCs in which WP1066 did
not affect CCL-2 production (gCSC2 and gCSC4) produced only
very low levels of CCL-2 under either normoxic or hypoxic
conditions. WP744 reduced galectin-3 (79%–98%, P=0.09) in all
four gCSCs, and VEGF in 3/4 gCSCs (23%–41%, P=0.04), but
increased sCSF-1 production (105%–159%, P=0.05), and had no
Figure 3. The ability of gCSCs to inhibit phagocytosis in monocytes is enhanced by hypoxic conditions. A. Supernatants from gCSCs
cultured in normoxic and hypoxic conditions inhibited phagocytosis of fluorescent microbeads (red) in monocytes exposed to the supernatants for
72 h, with hypoxic supernatants inhibiting phagocytosis to a greater extent than normoxic supernatants for all 4 gCSCs tested. Representative high-
power fluorescent microscope images (40X) of monocytes exposed to (i) neurosphere medium alone as a positive control, (ii) normoxic gCSC
supernatant, and (iii) hypoxic gCSC supernatants. Cell nuclei were stained with DAPI (blue). B. *P,0.05 indicates a significant difference between
phagocytosis inhibition by hypoxic versus normoxic gCSC supernatants.
doi:10.1371/journal.pone.0016195.g003
Figure 2. Hypoxia enhances the gCSC-mediated immunosuppression on human T cells. A. When healthy donor peripheral blood
mononuclear cells (PBMCs) were cultured in the presence of supernatant medium from cultures of each of the gCSCs, T cell proliferation was
inhibited, as demonstrated by fluorescence-activated cell sorting (FACS) analysis of CD3+ T cell carboxyfluorescein diacetate succinimidyl ester (CFSE)
labeling that measures T cell proliferation. For each of the matched gCSCs under hypoxic conditions, T cell proliferation was further inhibited
compared to normoxia. Representative FACS histograms or dot plots are shown on the left, and the summary bar graphs of percentage changes are
shown on the right. T cells cultured with neurosphere cell medium served as a control. B. The supernatants from the gCSCs induced an increase in the
number of FoxP3
+ regulatory T cells in the gated CD4
+ T cells, which is further enhanced under conditions of hypoxia. C. The inhibition of IFNc
production in CD3+ T cells was enhanced under hypoxic condition compared to normoxia. * P,0.05.
doi:10.1371/journal.pone.0016195.g002
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measured by intracellular pSTAT3 (pY705) staining via flow cytometry. The mean fluorescent intensity of positive staining was determined by flow
cytometry analysis under both normoxic and hypoxic conditions for each gCSC (representative histogram was shown as A), and then the percentage
change was calculated compared with the expression of pSTAT3 in each gCSC under normoxic condition (shown as B). C and D. The HIF-1a
expression in the gCSCs was measured by intracellular HIF-1a staining via flow cytometry after culture in either hypoxic or normoxic culture
conditions: representative histogram was shown as B, and percentage changes of all 4 gCSCs under hypoxia compared to normoxic condition was
plotted as bar graphs in D. E. Confirmatory representative western blot demonstrating that pSTAT3 and HIF-1a expression is increased within gCSCs
after hypoxia exposure. There was no change for total STAT3 expression.
doi:10.1371/journal.pone.0016195.g004
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gCSC1, WP1066 and WP744 did not affect VEGF production;
but hypoxia had the least substantial effect on VEGF production
relative to normoxia in gCSCs (Fig. 1).
We next addressed the potency of these agents in reversing
hypoxia-exposed gCSC-mediated immunosuppression. At physio-
logical levels that can be obtained in vivo, WP1066 was more
potent than WP744 at restoring T cell proliferative responses
(Fig. 6A). In contrast, WP744 was able to inhibit the hypoxia-
induced CD4+FoxP3+ T cell to a greater degree than WP1066
(Fig. 6B). WP1066 and WP744 were equally effective in restoring
monocyte phagocytosis inhibition (Fig. 6C). WP1066 increased
phagocytosis to 86.0% in comparison to neurosphere medium
positive control (range 75.6% to 97.3%, P=0.01) and WP744
increasing phagocytosis to 90.0% (range 87.3% to 92.3%,
P=0.0006).
Discussion
In this investigation we demonstrated that tumor hypoxia
potentiates glioma-mediated immunosuppression of both innate
and adaptive immunity. We had previously shown that the gCSCs
induced regulatory T cells [3]; however, during blocking
experiments of TGF-b, we could not completely ablate the
induction of regulatory T cells (unpublished data) indicating that
other cytokines had a role in triggering the formation of regulatory
T cells. Under conditions of hypoxia, there was a marked increase
of HIF-1a by the gCSCs. A previous report has demonstrated that
hypoxia can increase HIF-1a levels and subsequent FoxP3
expression in T cells along with their corresponding potency in
suppressing effector T cells [10]. It has been proposed by Sitkovsky
et al., [44] that maximal immunosuppression is only possible if the
T cell receptor (TCR)-triggered activities of immunosuppressive
regulatory T cells are combined with and/or enhanced by tissue
hypoxia via the adenosine receptor [45]. Our studies support this
contention because T cell proliferation and the induction of
regulatory T cells were potentiated in hypoxic conditions.
Macrophages have previously been demonstrated in hypoxic
areas of tumors [46,47,48] likely recruited by tumor-elaborated
factors [49,50]. However, in contrast to other investigators who
found that hypoxia directly enhanced monocyte/macrophage
phagocytosis [51,52,53], we found that hypoxic exposed gCSCs
inhibited monocyte/macrophage phagocytosis emphasizing the
importance of the tumor microenvironment and cell-to-cell
interactions in determining immunological responses.
The role of hypoxia on subverting macrophages to TAM/M2
phenotype and function likely involves both HIF-1a-dependent and
independent processes. Hypoxic conditions increased the ability of
gCSCs to induce pSTAT3 expression in monocytes – a defining
characteristic of the M2 macrophage [54]. However, this did not
result in an increase of monocyte/macrophage-elaborated immu-
nosuppressive cytokines or further reduction in the expression of co-
stimulatory and MHC molecules needed for antigen presentation
on the monocytes/macrophages, indicating that hypoxia is not
solely responsible for polarizing the monocytes toward a function-
ally immunosuppressive phenotype. It’s also possible that after
monocytes are freshly recruited into hypoxic areas of tumor, their
further polarization towards M2 and otherwise tumor-supportive
macrophage phenotypes (including the induction of immune
suppressive and/or pro-angiogenic cytokines) may be directly
mediated by the hypoxic environment itself [55], in addition to
the direct activities of gCSCs. For example, although we did not
observe inductionofVEGF production inmonocytesexposedtothe
supernatants from either normoxic or hypoxia-exposed gCSCs,
VEGF production in macrophages has been shown to be induced
directly by hypoxia [56].
In practice, we are exploiting the gCSCs as an immunosup-
pressive cell population to evaluate the role of hypoxia given the
gCSCs propensity to recapitulate many of the hallmark features of
malignant gliomas, including immunosuppression; however it is
unlikely that hypoxia exerts effects exclusively to this population.
Hypoxia induced an increase in the production of the immuno-
suppressive cytokines by the gCSCs such as galectin-3 and VEGF,
regulatory T cell and macrophage chemoattractants sCSF-1 [19]
and CCL-2 [21,57], and HIF-1a [10] but the gCSC is unlikely to
be the sole source of these cytokines within the tumor
microenvironment. It has also been suspected that hypoxia may
influence the levels or activity of CTLA-4 and/or B7-H1 [58].
Although we did not find differences in the expression of CTLA-4
or B7-H1 under conditions of hypoxia, we can’t discount the
possibility of alterations in the transcriptional activities of these
receptors.
To determine whether STAT3 and HIF-1a inhibitors can
reverse the hypoxia-exposed gCSC-mediated immunosuppressive
effects, we treated the gCSCs with WP744 and WP1066 under
hypoxic conditions. WP1066 in comparison to WP744 had a more
potent effect on reduction of immunosuppressive cytokines such as
galectin-3, CCL-2 and sCSF-1 elaborated by the gCSCs under
hypoxia likely secondary to WP1066 inhibiting the immune
suppressive pathway pSTAT3. Both of these agents were capable
of inhibiting HIF-1a, with WP744 being more potent. The
immunological effects of inhibiting HIF-1a were most evident in
the inhibition of induced FoxP3+ T cells in which WP744 exerted
the greatest effect. However, WP1066, which also exert potent
STAT3 inhibitor activity, exerted a greater and more global
reversal of gCSC-mediated immunosuppression on effector
responses, especially adaptive T cell proliferation and effector
function, although this was not absolute. This indicates that
hypoxia is a significant inducer of gCSC-mediated immunosup-
pression but that this can’t be overcome by HIF-1a inhibitors
alone or that the current generation of STAT3 inhibitors can
completely restore immunological responsiveness to the levels seen
in normal control. Further investigations will be necessary to
ascertain how to optimize the STAT3 inhibitors in combination
with other immune therapeutics in the setting of hypoxic tumor
microenvironments.
Figure 5. WP1066 inhibits pSTAT3 and HIF-1a expression, whereas WP744 only inhibits HIF-1a expression in gCSCs. A and B. WP744
or WP1066-treated, hypoxia and normoxia exposed gCSCs express lower levels of HIF-1a than gCSCs exposed to hypoxia and normoxia alone. The
HIF-1a expression in the gCSCs cultured under normoxia and hypoxic conditions was measured by intracellular staining via flow cytometry in the
presence or absence of WP744 or WP1066. Representative histograms were shown as A. The percentage changes of all 4 gCSCs under hypoxia and
normoxia were compared to untreated gCSCs and then the corresponding percentage change of expression was calculated and plotted as bar
graphs in B. C and D. WP1066 inhibited pSTAT3 expression in gCSCs under both normoxia and hypoxia, whereas WP744 enhances pSTAT3
expression. The pSTAT3 expression in the gCSCs under normoxia and hypoxic conditions was measured by intracellular pSTAT3 staining via flow
cytometry in the presence or absence of WP744 or WP1066. Representative histograms were shown as C, and percentage changes of all 4 gCSCs
under hypoxia and normoxia were plotted as bar graphs in D. In histograms, dashed line represented isotype staining and the black line staining for
either HIF-1a or pSTAT3. The number in histograms represented positive percentage for pSTAT3 or HIF-1a relative to the isotype. *P,0.05.
doi:10.1371/journal.pone.0016195.g005
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immunosuppression in human T cells to a greater degree than WP744. When healthy donor PBMCs were cultured in the presence of each of the
supernatants conditioned by the gCSCs, T cell proliferation was inhibited, as demonstrated by FACS analysis on CFSE labeled T cell division. This
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This study demonstrates that hypoxia increases the ability of
gliomas to induce immunosuppressive cells such as Tregs and M2
macrophages and thus plays a key role in both tumor-mediated
innate and adaptive immune suppression. These findings also help
to reconcile the disparate findings that immune therapeutic
approaches can be used successfully in preclinical model systems
but have yet to achieve successful responses in the vast majority of
patients by demonstrating the importance of the tumor hypoxic
environment in markedly inducing the immune suppressive
properties of the GBM. The tumor hypoxia induced immune
suppression is modulated by the signal transducer and activator
transcription 3 (STAT3) pathway and hypoxia inducible factor
(HIF)-1a, which can be reversed with STAT-3 and HIF-1a
inhibitors and indicates hypoxia-mediated immune suppression
can be overcome with inhibitors. These agents should be included
in the armamentarium of agents to reverse tumor-mediated
immune suppression. These findings contribute to understanding
the mechanisms that impact tumor-mediated immunosuppression
and provides an approach for optimizing immune therapeutic
strategies.
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